Jianping Li

Jianping Li

Auto-generated profile, based on publicly available information

Jianping Li

Division of Hematology/Oncology, University of Florida Health Cancer Center, University of Florida, Gainesville, FL

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DNDavid Y. Nie
David Y. Nie
JTJohn R. Tabor
John R. Tabor
JLJianping Li
Jianping Li
MKMaria Kutera
Maria Kutera
JSJonathan St-Germain
Jonathan St-Germain
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith

1 August 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
SLShihong Lu
Shihong Lu
MGMeili Ge
Meili Ge
YZYizhou Zheng
Yizhou Zheng
JLJianping Li
Jianping Li
XFXiaoming Feng
Xiaoming Feng
ZHZhongchao Han
Zhongchao Han
Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients. We used Illumina HiSeqTM 2000 sequencing, quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry (FCM), and Western blotting to test the expression of CD106 gene (vascular cell adhesion molecule 1 (VCAM1)) and CD106 protein of BM-MSCs. Furthermore, we used hematoxylin and eosin (H&E) and histochemical staining analysis, immunofluorescence, and the formation of capillary-like structures to analyze capillary tube-like formation in vitro; we also used the Matrigel plug assay to test in vivo vasculogenesis, and an assay of colony forming units (CFUs) and colony-forming unit-megakaryocyte (CFU-MK) to detect the support function of MSCs in vitro. The in vivo engraftment of CD34+ cells and MSCs in NOD/SCID mice was tested by FACS and survival assay; the expression of NF-κB was tested by NanoPro analysis and immunofluorescence. NF-κB-regulated CD106 gene (VCAM1) was confirmed by tumor necrosis factor alpha (TNF-α)-stimulated and lipopolysaccharide (LPS)-stimulated MSCs, blockade assay, and immunofluorescence. Here, we report that BM-MSCs from AA patients exhibited downregulation of the CD06 gene (VCAM1) and low expression of CD106 in vitro. Further analysis revealed that CD106+ MSCs from both AA patients and healthy controls had increased potential for in vitro capillary tube-like formation and in vivo vasculogenesis compared with CD106– MSCs, and the results were similar when healthy MSCs were compared with AA MSCs. CD106+ MSCs from both AA patients and healthy controls more strongly supported in vitro growth and in vivo engraftment of CD34+ cells in NOD/SCID mice than CD106– MSCs, and similar results were obtained when healthy MSCs and AA MSCs were compared. The expression of NF-κB was decreased in AA MSCs, and NF-κB regulated the CD106 gene (VCAM1) which supported hematopoiesis. These results revealed the effect of CD106 and NF-κB in BM failure of AA.

1 November 2019 in Oral Oncology
Verified
Journal Article
Closed access
YJYue Jiang
Yue Jiang
RGRuli Gao
Ruli Gao
CCChunxia Cao
Chunxia Cao
LFLauren Forbes
Lauren Forbes
JLJianping Li
Jianping Li
FKFrederic J. Kaye
Frederic J. Kaye

3 October 2024 in Blood
Verified
Journal Article
Open access
DDDaphné Dupéré-Richer
Daphné Dupéré-Richer
ARAlberto Riva
Alberto Riva
BBBenjamin G. Barwick
Benjamin G. Barwick
SMSayantan Maji
Sayantan Maji
HRHeidi Casellas Román
Heidi Casellas Román
JLJonathan D. D Licht
Jonathan D. D Licht
The histone H3 at lysine 27 (H3K27) demethylase lysine demethylase 6A (KDM6A) is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome-wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA, which encode regulators of major histocompatibility complex genes. Patient data indicate that NLRC5 and CIITA are downregulated in MM with low KDM6A expression. Chromatin analysis shows that KDM6A binds poised and active enhancers and KDM6A loss led to decreased H3K27ac at enhancers, increased H3K27me3 levels in body of genes bound by KDM6A, and decreased gene expression. Reestablishing histone acetylation with an HDAC3 inhibitor leads to upregulation of major histocompatibility complex expression, offering a strategy to restore immunogenicity of KDM6A-deficient tumors. Loss of Kdm6a in Kirsten rat sarcoma virus (K-RAS)-transformed murine fibroblasts led to increased growth in vivo associated with decreased T-cell infiltration.

28 October 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KVKartika Venugopal
Kartika Venugopal
YFYang Feng
Yang Feng
PNPawel Nowialis
Pawel Nowialis
HXHuanzhou Xu
Huanzhou Xu
DSDaniil E. Shabashvili
Daniil E. Shabashvili
OGOlga Guryanova
Olga Guryanova
Purpose: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage response and replication fork integrity, suggesting sensitivity to replication stress. Here, we tested whether pharmacologically induced replication fork stalling, such as with cytarabine, creates a therapeutic vulnerability in cells with DNMT3A(R882) mutations. Experimental Design: Leukemia cell lines, genetic mouse models, and isogenic cells with and without DNMT3A(mut) were used to evaluate sensitivity to nucleoside analogues such as cytarabine in vitro and in vivo, followed by analysis of DNA damage and signaling, replication restart, and cell-cycle progression on treatment and after drug removal. Transcriptome profiling identified pathways deregulated by DNMT3A(mut) expression. Results: We found increased sensitivity to pharmacologically induced replication stress in cells expressing DNMT3A(R882)-mutant, with persistent intra–S-phase checkpoint activation, impaired PARP1 recruitment, and elevated DNA damage, which was incompletely resolved after drug removal and carried through mitosis. Pulse-chase double-labeling experiments with EdU and BrdU after cytarabine washout demonstrated a higher rate of fork collapse in DNMT3A(mut)-expressing cells. RNA-seq studies supported deregulated cell-cycle progression and p53 activation, along with splicing, ribosome biogenesis, and metabolism. Conclusions: Together, our studies show that DNMT3A mutations underlie a defect in recovery from replication fork arrest with subsequent accumulation of unresolved DNA damage, which may have therapeutic tractability. These results demonstrate that, in addition to its role in epigenetic control, DNMT3A contributes to preserving genome integrity during replication stress. See related commentary by Viny, p. 573

31 March 2023
Verified
Other
Open access
KVKartika Venugopal
Kartika Venugopal
YFYang Feng
Yang Feng
PNPawel Nowialis
Pawel Nowialis
HXHuanzhou Xu
Huanzhou Xu
DSDaniil E. Shabashvili
Daniil E. Shabashvili
OGOlga A. Guryanova
Olga A. Guryanova
Supplementary Data from DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks